I also believe the biggest positive for me, similar to the BH deal, are these high-profile individuals validate the product.
Regarding their tardiness, however, they were supposed to commence the pre-clinical trials of Remplir for the FDA in Q4 of 2022 and then in Q1 23, I believe. Yet to hear anything from them in that regard. I hope they don't dawdle with the ATI results in May.
I also believe the biggest positive for me, similar to the BH...
Add OCC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
65.5¢ |
Change
-0.030(4.38%) |
Mkt cap ! $156.6M | |||
| Open | High | Low | Value | Volume |
| 67.0¢ | 67.0¢ | 65.5¢ | $177.5K | 267.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 32772 | 65.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 66.0¢ | 12102 | 3 |
View Market Depth
| Last trade - 13.41pm 13/11/2024 (20 minute delay) ? |
| OCC (ASX) Chart |